Friday, November 6, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

Rafael Santana-Davila, MD

Rafael Santana-Davila, MD

Swedish Cancer Institute

Rafael Santana-Davila, MD, is a board-certified medical oncologist at Swedish Cancer Institute in Seattle, where he focuses on thoracic malignancies and novel therapeutics, including phase 1 drug development. He earned his medical degree in Mexico City, completed his internal medicine residency at the University of Minnesota, and completed his fellowship at Mayo Clinic in Rochester, Minnesota. He remains active in academic medicine and clinical trial development in lung cancer, and has built tools to help himself and colleagues keep up with the pace of literature and conference updates in the field.

Published Articles (1)

Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming

July 16, 2026

Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.